Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 4, 2010, Pages 281-284

  Apostolidou, Effrosyni ^a   Kantarjian, Hagop ^a   Thomas, Deborah ^a   Burger, Ian ^a   Borthakur, Gautam ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hydroxyurea; Lenalidomide; Myeloproliferative neoplasm; SU5416; Vatalanib

Indexed keywords

CYTOKINE; GROWTH FACTOR RECEPTOR; HEMOGLOBIN; PIRFENIDONE; PROTEIN TYROSINE KINASE; SUNITINIB; VASCULOTROPIN; VATALANIB; ANAGRELIDE; AZACITIDINE; BORTEZOMIB; HYDROXYUREA; INTERFERON; LENALIDOMIDE; OBATOCLAX; SEMAXANIB;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT AND MOUTH DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INDIGESTION; LEUKOPENIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; NAUSEA AND VOMITING; OSTEOSCLEROSIS; PAPILLEDEMA; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; RASH; STOMATITIS; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEMOGLOBIN DETERMINATION; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; PATIENT COMPLIANCE; SYMPTOM; VOMITING;

EID: 77957068128     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.058     Document Type: Article

References (24)

1. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895-901.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342:1255-65.
3. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102:684-90.
4. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013-8.
5. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93:2831-8.
6. Martyre MC. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 1995; 20:39-44.
7. Chagraoui H, Komura E, Tulliez M, et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002; 100:3495-503.
8. Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96:3374-80.
9. Ho CL, Arora B, Hoyer JD, et al. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74:35-9.
10. Martyré MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994; 88:9-16.
11. SU011248 [Investigator's Brochure]. Pfizer IaA. New York, NY; 2005.
12. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37.
13. Sakamoto KM. Su-11248 Sugen. Curr Opin Investig Drugs 2004; 5:1329-39.
14. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105:986-93.
15. Houk BE, Bello CL, Kang D et al. A population pharmacokinetic metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15:2497-506.
16. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31:737-40.
17. Panteli K, Bai M, Hatzimichael E, et al. Serum levels, and bone marrow immu-nohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology 2007; 12:481-6.
18. Boveri E, Passamonti F, Rumi E, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 2008; 140:162-8.
19. Arora B, Ho CL, Hoyer JD, et al. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica 2004; 89:1454-8.
20. Mesa RA, Tefferi A, Elliott MA, et al. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114:111-3. (Pubitemid 32702642)
21. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-89.
22. Giles FJ, List AF, Carroll M, et al. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res 2007; 31:891-7.
23. Giles FJ, Cooper MA, Silverman L, et al. Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer 2003; 97:1920-8.
24. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25:884-96.